Editas Medicine, Inc. (EDIT) is a Cambridge, Massachusetts-based clinical-stage genome editing company built on CRISPR/Cas9 and Cas12a technology. Following its decision to wind down the ex vivo therapy reni-cel and focus on in vivo medicines, the company's lead program is now EDIT-401, an investigational gene-editing treatment designed to upregulate the LDL receptor in the liver to durably lower LDL ("bad") cholesterol, initially targeting heterozygous familial hypercholesterolemia (HeFH).
The stock price target of $6.60 used here is an arithmetic mean of eight verified analyst price targets, rounded to a clean level, and it sits far above the stock's recent trading range. This article examines whether such a move is plausible, what would need to go right, and what could stand in the way.
Eight current, attributable analyst targets were reviewed to calculate the central target. The individual targets and firms are: Evercore ISI at $15 (Outperform, reiterated May 2026); JonesTrading at $8 (Buy, maintained August 2026); Ladenburg Thalmann at $6 (Buy, initiated August 2026); Wells Fargo at $6 (Overweight, upgraded October 2026); Guggenheim at $5 (Buy, upgraded September 2026); H.C. Wainwright at $5 (Buy, reiterated August 2026); RBC Capital at $4 (Hold, maintained August 2026); and Chardan Capital at $4 (Buy, May 2026).
The resulting mean is about $6.63, which rounds to the $6.60 central target. The approximate low-to-high range is $4.00 to $15.00, an unusually wide spread. Bullish analysts argue that EDIT-401's strong preclinical LDL-C reductions in non-human primates support meaningful clinical potential, with Evercore ISI's $15 target reflecting a far more aggressive view of the program's value. More cautious analysts, such as RBC Capital's Hold with a $4 target, emphasize the early stage of the pipeline and limited visibility. Bank of America Securities maintains a Sell rating without a published target, underscoring that not every firm shares the constructive stance.
With EDIT recently trading around $2.60, reaching $6.60 would require roughly 154% appreciation, a very large move. The stock has traded between a 52-week low near $1.66 and a high near $4.28, so the central target sits far above the stock's recent peak.
Editas Medicine has no approved products; its revenue comes primarily from collaboration and licensing agreements, including a Cas9 license to Vertex Pharmaceuticals. The company reported full-year 2025 revenue of about $40.5 million and posted a narrower-than-expected quarterly loss in mid-2026. The path to a higher valuation rests almost entirely on the clinical de-risking of EDIT-401, rather than near-term earnings or profitability.
The principal catalyst is EDIT-401's advancement. Editas received clearance to initiate a first-in-human Phase 1/2 trial for EDIT-401 in HeFH in October 2026, and the company has guided toward early human proof-of-concept data. Analysts such as H.C. Wainwright and TD Cowen have cited the program's preclinical data showing substantial, durable LDL-C reductions as supportive of the translational hypothesis.
Management has also emphasized a cash runway extending into the third quarter of 2027, which analysts view as sufficient to fund the IND (investigational new drug) submission, trial initiation, and initial human data readout without immediate financing pressure. A favorable data readout, a partnership, or positive regulatory milestones could re-rate the shares meaningfully.
The risks are substantial. EDIT-401 is unproven in humans, and gene editing carries safety, efficacy, and regulatory uncertainties that could delay or derail development. Editas has a history of pipeline pivots, including the discontinuation of reni-cel, which previously pressured the shares. The company remains unprofitable and is expected to continue generating net losses, creating ongoing dilution risk even with the current cash runway.
Competition in both in vivo gene editing and the broader cardiovascular market is intense, and sentiment toward speculative biotech can shift quickly with broader risk appetite or sector rotation. The very wide analyst range, from $4 to $15, itself signals how uncertain the outcome remains.
From a technical standpoint, EDIT has recently traded below both its 50-day and 200-day simple moving averages, indicating a downtrend over the medium term. The 52-week range of roughly $1.66 to $4.28 frames the recent market structure, with the $4.00-to-$4.30 area representing a meaningful prior-high zone that the stock would first need to reclaim before the $6.60 target becomes relevant. A sustained move above the 200-day moving average would be a necessary early step in any longer-term trend reversal.
Analyst price targets generally reflect a research horizon of about 12 months, though firms may apply different assumptions. Investors should monitor initial EDIT-401 human data, IND/CTA (clinical trial application) progress and trial enrollment updates, upcoming quarterly earnings and cash-burn commentary, analyst revisions, and any partnership or financing announcements. The next earnings report is expected in November 2026.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot emerging trend shifts more efficiently than manual screening alone. For investors tracking a volatile name like EDIT, such tools can offer an additional, data-driven perspective alongside fundamental research.
The $6.60 central target, derived from the mean of eight analyst price targets, implies roughly 154% upside from a recent price near $2.60, a very large move that would require successful clinical de-risking of EDIT-401. Supporting the case are the program's encouraging preclinical data, first-in-human trial clearance, and a cash runway into 2027. Weighing against it are the absence of approved products, persistent losses and dilution risk, intense competition, and a wide analyst range from $4 to $15 that reflects genuine uncertainty. Reaching $6.60 is not a near-term expectation but a high-upside, high-risk scenario hinging primarily on clinical data and execution.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | +4.62% | ||
| BEAM - EDIT | 67% Closely correlated | +5.55% | ||
| PRME - EDIT | 63% Loosely correlated | +9.23% | ||
| CRSP - EDIT | 63% Loosely correlated | +3.57% | ||
| SLDB - EDIT | 62% Loosely correlated | +3.82% | ||
| VYGR - EDIT | 61% Loosely correlated | +2.19% | ||
More | ||||